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DSS in the squamous cell carcinoma subgroup (HR 0.62, 
95% CI 0.41–0.93, P  =  0.021). In contrast, there was an 
independent negative prognostic impact of T-CTLA-4 
expression in metastatic lymph nodes (HR 1.65, 95% CI 
1.03–2.65, P = 0.039). Our results indicate that the expres-
sion of CTLA-4 has diverging prognostic impacts in 
metastatic NSCLC lymph nodes versus primary tumors. 
The presented results highlight important differences in 
the tumor microenvironments of primary and metastatic 
NSCLC tissues, and have potential to guide treatment and 
clinical sampling strategies.
Keywords CTLA-4 · Prognostic · Non-small cell lung 
cancer · Immune checkpoints · Immunoscore
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CTLA-4  Cytotoxic T-lymphocyte-associated antigen-4
DSS  Disease-specific survival
ECOG  Eastern Cooperative Oncology Group
EGFR  Epidermal growth factor receptor
KRAS  Kirsten ras oncogene homolog
LCC  Large cell carcinoma
LN+  Metastatic lymph nodes
N+  Node positive
NSCLC  Non-small cell lung cancer
PD-1  Programmed death 1 receptor
PD-L1  Programmed death ligand 1
PT  Primary tumor
S-  Stromal
SCC  Squamous cell carcinoma
T-  Tumor epithelial
TMA  Tissue microarray
TNM  Tumor lymph node metastasis stage
Abstract The immune checkpoint receptor CTLA-4 plays 
a crucial part in negatively regulating T cell activation and 
maintaining self-tolerance. It is frequently overexpressed in 
a variety of malignancies, yet its prognostic impact in non-
small cell lung cancer (NSCLC) remains unclear. We con-
structed tissue microarrays from tumor tissue samples and 
evaluated the immunohistochemical expression of CTLA-4 
in 536 patients with primary resected stage I–IIIA NSCLC. 
Expression of CTLA-4 was analyzed in tumor and stromal 
primary tumor tissue and in locoregional metastatic lymph 
nodes. CTLA-4 expression in neither tumor epithelial cells 
(T-CTLA-4) nor stromal cells (S-CTLA-4) of primary 
tumors was significantly associated with disease-specific 
survival (DSS) in all patients. However, high S-CTLA-4 
expression independently predicted significantly improved 
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Introduction
Non-small cell lung cancer (NSCLC) mortality is high 
and there is a strong need for novel prognostic biomarkers 
to improve prediction of patient outcomes, to aid clinical 
decision-making and increase survival [1, 2]. Following the 
recent impressive results observed targeting the immune 
system in cancer therapy, biomarker research focus has 
turned to the tumor microenvironment. Different subsets 
of tumor infiltrating immune cells interact with malig-
nant cells in a complex and dynamic ecosystem, mediat-
ing immune surveillance and destruction of cancer cells 
as well as pro-tumoral inflammation [3, 4]. In fact, exten-
sive research supports that the immune contexture has an 
impact on cancer patient outcomes [5]. Recently, quantifi-
cation of the in situ immune infiltrate was found to supple-
ment the prognostic accuracy of the TNM classification in 
breast cancer, colorectal cancer and NSCLC, the two latter 
applying an “Immunoscore” method [6–8].
CTLA-4 (Cytotoxic T-lymphocyte-associated antigen-4, 
CD152) is the receptor of an immune checkpoint pathway 
that plays a crucial role in the regulation of T cell activation 
and preservation of self-tolerance. Hence, its expression in 
the tumor microenvironment constitutes a potential prog-
nostic and predictive biomarker in NSCLC patients [9].
T cells are activated in secondary lymphoid organs, 
when the T cell antigen receptor recognizes antigen-MHC 
complexes on antigen-presenting cells (APCs). A costimu-
latory signal is elicited by the engagement of CD28 on T 
cells with B7 ligands (CD80 and CD86) on APCs [10]. 
However, upon T cell activation, the CD28 homologue 
CTLA-4 is translocated from intracellular storage to the 
plasma membrane of T cells, competitively binding to B7 
ligands on APCs with higher affinity, thereby preventing 
CD28-mediated T cell activation [9]. While naïve T cells 
upregulate CTLA-4 only after activation, regulatory T cells 
constitutively express CTLA-4, and the result of CTLA-4 
ligation is mediation of the suppressive function of regu-
latory T cells and inhibition of conventional T cells, but 
the exact molecular mechanisms remain to be elucidated 
[11, 12]. Expression in non-T cell subsets has also been 
observed, though its role remains uncertain [13–17].
Sustained overexpression of CTLA-4 is often induced in 
chronic inflammation and cancer, implying that CTLA-4 in 
the tumor microenvironment may be involved in dysregu-
lation of the immune response in cancer [18, 19]. Moreo-
ver, monoclonal antibodies targeting CTLA-4 enhance T 
cell mediated anti-tumor immunity [20–22]. Yet, studies 
examining the prognostic impact of CTLA-4 expression 
in NSCLC tumor tissue are few and inconclusive [23–26]. 
How CTLA-4 expression is distributed in primary tumors 
(PTs) and metastatic sites, and how this might influence 
patient outcome, is presently unclear. Hence, to increase 
the understanding of the natural course of NSCLC, further 
research on the roles of CTLA-4 expression in NSCLC, 
which can potentially guide treatment preferences and 
tumor sampling strategies, is needed.
Hypothesizing that CTLA-4 is a candidate prognos-
tic biomarker for inclusion in a NSCLC Immunoscore, 
we aimed to explore the prognostic impact of CTLA-4 in 
tumor epithelial and stromal cells of PTs from 536 resected 
stage I-IIIA NSCLC patients as well as in 142 matched 
lymph node metastases (LN+).
Materials and methods
Patients and clinical samples
PT tissues from an unselected patient population who 
underwent radical resection for NSCLC pathologic stage I 
to IIIA at the University Hospital of North Norway and the 
Nordland Hospital from 1990 to 2010, were retrospectively 
collected. In total, 536 patients with complete medical 
records and adequate paraffin-embedded tissue blocks were 
eligible, as previously described, including 142 patients 
with available lymph node specimens out of the 172 
patients with N+ disease [27]. This report includes follow-
up data as of October 1, 2013. Median follow-up time of 
survivors was 86 months (range 34–267 months). The Nor-
wegian Data Protection Authority and the Regional Com-
mittee for Medical and Health Research Ethics approved 
the study (Protocol ID: 2011/2503), and the need for patient 
consent was waived. Reporting of clinicopathological vari-
ables, survival data, and biomarker expressions was con-
ducted in accordance with the REMARK guidelines [28].
Microarray construction
All tissues were histologically reviewed by two patholo-
gists. The most representative areas of viable neoplastic 
epithelial cells and of tumor stroma in the PT and matched 
LN+ were carefully selected for the tissue microarrays 
(TMAs). Cores were not consistently taken from specific 
tumor areas, such as central tumor or invasive margin. 
TMAs were assembled using a tissue-arraying instrument 
(Beecher Instruments, Silver Springs, MD, USA). The 
detailed methodology has been previously reported [29]. 
Briefly, we used a 0.6-mm diameter stylet. Four cores were 
sampled from different areas in the two compartments, two 
from tumor epithelium and two from tumor stroma.
Immunohistochemistry
The antibodies evaluated for CTLA-4 expression were 
mouse monoclonal CD152 (eBioscience, clone: 14D3, 
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Cat#14-1529) and rabbit polyclonal CTLA-4 (Abcam, 
Cat#ab151773). Antibodies were subject to in-house vali-
dation by the manufacturer. In addition, we performed vali-
dation by staining multi-organ TMAs as positive and nega-
tive tissue controls, and transfectant plasmid cell lysates 
(See CD152 Antibody Validation). Normal placenta sec-
tions served as positive tissue controls, negative tissue con-
trols comprised sections of normal brain tissue. Only the 
CD152 (clone 14D3) antibody fulfilled the standards for 
evaluation and was used in this study.
Immunohistochemical analyses were performed on Dis-
covery-Ultra immunostainer (Ventana Medical Systems, 
Tucson, AZ). Slides were deparaffinized in three 8-min 
cycles, and heated overnight at 60  °C. For on-board anti-
gen retrieval, slides were incubated with Cell Conditioning 
Solution 1 (CC1) buffer for 24  min. Endogenous peroxi-
dase was blocked by Discovery inhibitor (Cat#760-4840) 
for 8 min. The CD152 primary antibody in 1/100 dilution 
was loaded and slides were incubated for 32 min at 37 °C. 
Slides were developed using OmniMap anti-mouse HRP 
(Cat#760-4310) for 20  min, followed by chromogenic 
detection kit ChromoMap DAB (Cat#760-159). Finally, 
to visualize the nuclei, all slides were counterstained with 
Ventana Hematoxylin II reagent (Cat# 790-2208) for 
32 min, followed by a Bluing reagent (Cat# 760-2037) for 
8 min. Slides were then dehydrated, cleared and mounted 
as in routine processing. Control staining by (1) omis-
sion of the primary antibody and by (2) incubation with 
a subclass isotype-matched control antibody (Biolegend, 
Cat#400203), omitting the CD152 primary antibody, was 
also performed.
CD152 antibody validation
Cell lysates from CTLA-4 transiently transfected HEK293 
cells (HEK293T, Cat#LY417438) and from empty vector 
transfected cells (HEK293, Cat#LY500001/negative con-
trol) were applied from OriGene; they were incubated with 
2xSDS Sample Buffer for 10 min at 100 °C. Equal amounts 
of protein lysates were resolved onto a 4–12% Bis–Tris gel 
(Cat#NP0322, Life Technologies). The resolved proteins 
were transferred onto an Odyssey nitrocellulose mem-
brane (#926-31092, LI-COR), and the membrane was 
subsequently blocked for 1  h at room temperature using 
the Odyssey blocking buffer (Cat#927-40000, LI-COR). 
CD152 antibody (clone 14D3) in a 1/100 dilution was 
applied, and the membrane incubated overnight at 4  °C. 
Subsequently, goat anti-mouse IRDye 800CW second-
ary antibody (Cat#926-32210, LI-COR) in 1/10.000 dilu-
tion was added, and incubated for 1 h at room temperature. 
Between antibody incubations, the membrane was washed 
three times for 5  min each time in tris-buffered saline 
containing 0.05% Tween 20 (Sigma-Aldrich). Molecular 
weight markers used were MagicMark XP Western Pro-
tein Standard (LC5603, Invitrogen) and SeeBlue Plus2 
Pre-stained Standard (#LC5925, Invitrogen). The most 
prominent bands represent the observed molecular weight 
(30  kDa) of the detected protein, which corresponds inti-
mately with the predicted weight provided by the manufac-
turer (24.66 kDa) (supplementary Fig. 1). Rabbit anti-actin 
(Cat#A2066, Sigma-Aldrich), 1:1000, was used as internal 
control and the lanes show 42 kDa molecular weight pro-
tein load.
Scoring of IHC
Samples were anonymized and independently scored by 
two of the authors (TK and EP), under the supervision of 
an experienced pathologist (ER), who established a semi-
quantitative score for each marker. When assessing a given 
core, the observers were blinded to each other, to clinical 
variables and to outcome. Tumor epithelial and stromal 
compartments were scored separately. Strongly stain-
ing cells morphologically consistent with macrophages 
were excluded from scoring, as the staining may represent 
ingested debris rather than macrophage staining.
Because staining of CTLA-4+ cells was relatively 
homogenous, both within tumor cells in the tumor epi-
thelial compartment and within the different stromal cells 
in the stromal compartment, the percentage (density) of 
CTLA-4 positive cells did not add valuable information to 
the score, and was not included. Intensity of CTLA-4 stain-
ing was scored as 0 (no staining), 1 (weak), 2 (moderate), 
and 3 (strong) in both the tumor epithelial (T-CTLA-4) and 
stromal (S-CTLA-4) compartments. As CTLA-4 staining 
was present in both tumor epithelial cells and immune cell 
subsets infiltrating the tumor epithelium, we were unable 
to precisely evaluate and score CTLA-4+ intraepithelial 
immune cells due to overlap of the chromogenic DAB sub-
strate. Identical scoring approaches were used in PTs and 
LN+. Two cores were sampled from each compartment 
(tumor epithelial and stromal) and scored by two indi-
viduals, hence four or two (if one TMA core was missing) 
scores were available. Based on the mean value of these 
scores, the threshold value for dichotomization of patients 
was determined. The cutoff that resulted in the minimal P 
value with regard to difference in outcome between the two 
groups was chosen (optimal cutoff). Accordingly, a high 
score was defined as >2.00 for S-CTLA-4 and >1.25 for 
T-CTLA-4. Figure 1 illustrates IHC scoring of CTLA-4 in 
PTs and LN+.
Scoring of other immunological markers previously 
analyzed by our group: CD3, CD4, CD8, CD45RO, CD20, 
PD-1 (programmed death 1 receptor), PD-L1 (programmed 
death ligand 1), has been previously described [27, 30–33].
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Statistical methods
All statistical analyses were performed using the SPSS 
statistical package (version 22, SPSS, Chicago, IL, USA). 
The IHC scores from each observer were compared for 
interobserver reliability by use of a two-way random 
effects model with absolute agreement definition, yield-
ing an intraclass correlation coefficient (reliability coeffi-
cient) and Cohen’s kappa. DSS (disease-specific survival) 
was defined as the time from surgery to lung cancer 
death.
The χ2 test or Fisher’s exact test was used to examine 
the association between molecular marker expression and 
various clinicopathological parameters. Spearman’s rank 
correlation was used to examine the associations between 
marker expressions. Univariate analysis of survival accord-
ing to each immune marker was visualized using the 
Kaplan–Meier method, and statistically significant differ-
ences between survival curves were assessed by the log-
rank test. For univariate analyses, unadjusted Cox propor-
tional hazard ratios were calculated. Multivariate analysis 
was performed using the Cox proportional hazards model, 
testing the simultaneous influence on survival of all covari-
ates found to be significant in the univariate analyses. The 
backward conditional method was used for model fitting. 
Probability for stepwise entry and removal was set at 0.05 
and 0.10, respectively. P values  <  0.05 were considered 
statistically significant. Correction for multiple testing was 




Demographic, clinical and histopathological variables for 
all 536 patients and their impact on DSS are presented 
in Table  1. Of the 172 patients with N+ disease, 142 
had adequate paraffin-embedded tumor specimens from 
tumor, and were included in this study (Clinicopathologi-
cal variables of N+ patients is presented in supplemen-
tary Table 1). Median age was 67 (range 28–85) years and 
68% of the patients were men. Due to nodal metastasis or 
non-radical surgical margins, 76 patients (14%) received 
postoperative radiotherapy. Forty-three patients received 
adjuvant therapy following its introduction into Norwegian 
national guidelines in 2005. None of the patients received 
immunotherapy.
Expression of CTLA‑4 in primary tumors and resected 
metastatic lymph nodes
CTLA-4 staining was predominantly cytoplasmatic and 
rarely membranous. Staining intensity for CTLA-4 in tumor 
epithelial cells (T-CTLA-4) was relatively homogenous 
Fig. 1  CTLA-4 immunohistochemical analysis in primary tumors 
and metastatic lymph nodes. Immunohistochemical analysis of non-
small cell lung cancer representing low and high scores for tumor cell 
CTLA-4 expression in PTs (T-CTLA-4: a, e), stromal expression in 
PTs (S-CTLA-4: b, f), tumor cell expression in LN+ (T-CTLA-4: c, 
g), negative (d, brain) and positive tissue controls (h, placenta). Mag-
nification x 400
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within each tumor, with variable intensity between tumors. 
Similarly, staining intensity for CTLA-4 in the different 
cell types in the stromal compartment (S-CTLA-4) was 
relatively homogenous within each tumor, and CTLA-4+ 
cells were dominated by cells morphologically consistent 
with immune cells. Thus, the stromal CTLA-4 (S-CTLA-4) 
intensity score is expected to mirror immune infiltration. 
The stromal component of lymph node metastasis was 
scarce and difficult to discern from normal lymph node tis-
sue; therefore, it was not scored.
The expression of tumor epithelial and stromal CTLA-4 
is presented in Table  2. The percentage of patients with 
high S-CTLA-4 (50%) was higher than that of T-CTLA-4 
(43%) (P  <  0.001) (percentage of non-missing cores). In 
PTs, the S-CTLA-4 and T-CTLA-4 mean scores were sig-
nificantly correlated (r = 0.329, P < 0.001). The percent-
ages of high T-CTLA-4 in PTs and LN+ (37%) were not 
significantly different (P  =  0.547). T-CTLA-4 expression 
in PTs and LN+ were not significantly correlated; in 56% 
of cases, T-CTLA-4 scores were concordantly high or low 
in PTs and LN+, while in 23% of cases, the PT score was 
high and LN+ score low, and in 21%, the opposite.
Associations with clinicopathological variables 
and immunological markers
There were no significant associations between expres-
sion of CTLA-4 in PTs or LN+ and age, sex, Eastern 
Cooperative Oncology Group (ECOG) performance sta-
tus, smoking, T-status, N-status, pathological stage, histo-
logical subgroup or vascular infiltration. In LN+ patients, 
high T-CTLA-4 was associated with poorly differentiated 
tumors (P = 0.034).
The S-CTLA-4 mean score in the PTs was, in both 
stromal and tumor epithelial compartments, extensively 
correlated with other immunological markers previ-
ously analyzed by our group (CD3, CD4, CD8, CD45RO, 
CD20, PD-1, PD-L1), while T-CTLA-4 in PTs was 
not (supplementary Table  2) [27, 30–33]. There was a 
strong and highly significant association between mean 
LN+ T-CTLA-4 and LN+ T-PD-L1 score (r  =  0.404, 
P < 0.001), while there were no correlations with the stro-
mal and tumor epithelial PT counterparts.
Interobserver reliability
Between-scorer agreement was excellent: the intraclass 
correlation coefficients were 0.894, 0.917 and 0.882, and 
Kappa values were 0.586, 0.696 and 0.589 for S-CTLA-4, 
PT T-CTLA-4 and LN+ T-CTLA-4, respectively (all vari-
ables, P < 0.001).
Univariate survival analyses
The prognostic impact of tumor epithelial and stromal 
CTLA-4 expression on DSS is presented in Table  2 and 
Fig.  2 (univariate analyses). Neither tumor epithelial nor 
stromal CTLA-4 expression predicted DSS for all patients, 
or for pathological stage subgroups (data not shown). 
Histological subgroup analyses showed that while high 
S-CTLA-4 was a positive prognostic factor for DSS (HR 
0.60, 95% CI 0.39–0.90, P = 0.013) in the SCC subgroup, 
no association with survival was found in the ADC and 
large cell carcinoma subgroups. T-CTLA-4 was a positive 
prognostic factor for DSS only in the ADC group (HR 0.64, 
95% CI 0.42–0.98, P = 0.037).
By combining the scores of CTLA-4 with other immu-
nological markers previously analyzed by our group (CD3, 
CD4, CD8, CD45RO, CD20, PD-1, PD-L1), we investi-
gated whether a combination of markers would improve 
the prognostic impact compared to single marker. Combin-
ing PT T-CTLA-4 or S-CTLA-4 scores with each of these 
markers did not contribute markedly to minimize P values 
or increase stratification according to 5-year DSS, for all 
patients or in histological subgroups (data not shown).
In metastatic lymph nodes, high expression of CTLA-4 
in tumor epithelial cells was associated with an adverse 
DSS (HR 1.65 95% CI 1.03–2.65, P = 0.037).
Multivariate analysis
Results from the multivariate Cox regression analyses are 
presented in Table 3. In PTs, S-CTLA-4 was an independ-
ent positive prognostic factor for DSS in the SCC subgroup 
(HR 0.62, 95% CI 0.41–0.93, P = 0.021), but not for ADC 
or all patients. T-CTLA-4 expression in PTs did not have 
a significant independent prognostic impact in all patients 
or in histological subgroups. High T-CTLA-4 expression in 
metastatic lymph nodes was an independent negative pre-
dictor of DSS (HR 1.65, 95% CI 1.03–2.65, P = 0.039).
Discussion
In our large, unselected NSCLC patient cohort, we demon-
strate that high expression of CTLA-4 on tumor epithelial 
cells in regional LN+ independently predicts poor DSS. In 
contrast, the expression of CTLA-4 in PTs was not signifi-
cantly associated with outcome in all patients. However, a 
high stromal CTLA-4 expression independently predicted 
prolonged DSS for patients with SCC histology. In addi-
tion, we observed no correlation between CTLA-4 expres-
sion in the PTs and the LN+. Strikingly, this illustrates that 
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phenotypical differences between the tumor microenviron-
ments of PTs and LN+ may result in diverging impacts on 
NSCLC prognosis.
To our knowledge, this is the largest published study 
analyzing prevalence and prognostic importance of 
CTLA-4 expression in NSCLC, and the first to assess both 
tumor and stromal cells of NSCLC PTs as well as matched 
LN+ [23–26, 34–36]. The antibody used was subject to 
careful validation, and between-scorer agreement was 
excellent.
With our methodology, we were not able to score stro-
mal CTLA-4 expression in LN+. In light of the independ-
ent impact of S-CTLA-4 in PTs, the delineation of stroma 
surrounding tumor islets in LN+ needs to be clarified, 
allowing assessment of CTLA-4 in the tumor microenviron-
ment of N+ disease in future studies. Due to their intimate 
interaction with tumor cells, the assessment of CTLA-4+ 
immune cells infiltrating the tumor epithelial compartment 
may have added significant value to the study. However, a 
confirmatory methodology, such as immunofluorescence 
dual staining of CD45 and CTLA-4, would be required 
to achieve a precise evaluation of these cells. Moreover, 
CTLA-4 expression in cores from central tumor and inva-
sive margin may have differing prognostic value, but con-
sistent sampling from distinct tumor areas within the tumor 
epithelial compartment were not included in the TMAs in 
this study [7]. Potential heterogeneity in CTLA-4 expres-
sion within the tumor tissue was minimized by analyzing 
Fig. 2  Survival curves. Disease-specific survival curves are shown 
according to PT expression of S-CTLA-4 (a–c) and T-CTLA-4 (d–
f) in all patients (a, d), squamous cell carcinoma (SCC) (b, e) and 
adenocarcinoma (ADC) (c, f) subgroups, and to the expression of 
T-CTLA-4 in LN+ of all patients with LN+ available (g), SCC (h) 
and ADC (i) subgroup
1458 Cancer Immunol Immunother (2017) 66:1449–1461
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cores from two to four areas of tumor and of stroma. Man-
ual, semi-quantitative scoring is a time- and cost-efficient 
method, but the interpretation of staining intensity is to 
some degree subjective and for future validation purposes, 
whole tissue slides and digital automated scoring of immu-
nohistochemistry should be considered.
The positive prognostic value of CTLA-4 expression in 
PTs was limited to histological subgroups, and was not a 
Table 3  Results of Cox regression analysis summarizing significant independent prognostic factors for disease-specific survival in primary 
tumors and metastatic lymph nodes (LN+)
Bold numbers are significant results
a In the same model. b Overall significance as a prognostic factor. c In separate models. All clinicopathological covariates significant in multi-
variate analysis (A) are included in each model
ECOG perf. status Eastern Cooperative Oncology Group performance status. HR hazard ratio. LCC large cell carcinoma. LN+ metastatic lymph 
nodes. NE not entered. PT primary tumor
Primary tumors LN+
All patients Squamous cell carcinoma Adenocarcinoma All patients
HR(95%CI) P HR(95%CI) P HR(95%CI) P HR(95%CI) P
A. Clinicopathological  variablesa
 Pathological stage <0.001b <0.001b <0.001b 0.047b
  IA 1.00 1.00 1.00
  IB 1.23(0.78–1.96) 0.377 0.98(0.43–2.22) 0.961 1.88(0.99–3.56) 0.052
  IIA 1.68(1.07–2.63) 0.023 1.91(0.98–3.74) 0.059 2.88(1.50–5.52) 0.001 1.00
  IIB 2.63(1.64–4.12) <0.001 3.35(1.70–6.61) <0.001 3.20(1.50–6.82) 0.003 1.09(0.50–2.38)
  IIIA 4.61(2.94–7.23) <0.001 6.86(3.43–13.73) <0.001 4.87(2.55–9.28) <0.001 1.73(1.10–2.71)
 Histology 0.003b NE




  No versus yes 1.75(1.26–2.44) 0.001 1.56(0.98–2.50) 0.061 1.56(0.91–2.70) 0.108
 Differentiation 0.005b 0.224 0.044 NE
  Well 1.00 1.00 1.00
  Moderate 1.80(1.05–3.09) 0.034 1.32(0.59–2.92) 0.498 2.24(1.10–4.52) 0.024
  Poor 2.36(1.37–4.05) 0.002 1.78(0.79–2.03) 0.165 2.39(1.19–4.77) 0.014
 Sex
  Female versus male 1.71(1.26–2.33) 0.001 NE 1.55(1.00–2.41) 0.049 NE
 ECOG perf. status 0.009b NE 0.006b NE
  0 1.00 1.00
  1 1.49(1.21–1.97) 0.006 1.58(1.03–2.43) 0.037
  2 1.78(1.00–3.19) 0.051 3.31(1.46–7.47) 0.004





  Free versus not free NE NE 1.41(0.66–3.01) 0.375 NE
B. Immunological  markersc
 PT S-CTLA-4 NE 0.021 NE
  Low versus high 0.62(0.41–0.93)
 PT T-CTLA-4 NE NE 0.834
  Low versus high 0.95(0.60–1.51)
 LN+ T-CTLA-4 0.039
  Low versus high 1.65(1.03–2.65)
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significant predictor of outcome in all pathological stages. 
Thus, CTLA-4 is not considered a good candidate for a 
NSCLC TNM-Immunoscore.
Our most striking finding was the independent nega-
tive prognostic impact of high T-CTLA-4 expression in 
metastatic lymph nodes. T-CTLA-4 in LN+ was not sig-
nificantly correlated to the expression of T-CTLA-4 in PTs. 
This demonstrates heterogeneity of tumor cell CTLA-4 
expression between PTs and LN+, probably brought about 
by genetic and epigenetic alterations acquired during tumor 
progression and metastasis [37]. In NSCLC, evidence sup-
ports that tumor cells sampled from the PT and metastatic 
sites display molecularly distinct characteristics; genetic 
heterogeneity between tumor cells in PTs and LN+ with 
regard to EGFR (epidermal growth factor receptor) and 
KRAS (Kirsten ras oncogene homolog) status and muta-
tional profiles of other actionable genes is not infrequent 
[38, 39]. Additionally, the observed heterogeneity of 
T-CTLA-4 expression within PTs in our study, combined 
with a lack of correlation with other immune markers, sup-
ports that CTLA-4 upregulation in tumor cells is mainly 
induced by intrinsic oncogenic mechanisms, rather than 
regulated by the surrounding inflammatory microenviron-
ment, as was previously reported for gastric cancer [40].
In line with our results in patients with LN+, recent 
studies in other carcinomas have reported that tumor 
CTLA-4 expression is a negative prognostic factor. This 
may indicate that increased CTLA-4 expression is associ-
ated with immunosuppression and acceleration of disease 
progression and metastasis, possibly mediated by tumor 
cell synthesis of soluble CTLA-4 [41–43]. On the other 
hand, a lack of association with outcome, as well as a 
favorable prognostic impact of T-CTLA-4, has also been 
reported [40, 44]. A study demonstrating in vitro induction 
of tumor cell apoptosis upon CTLA-4 engagement with B7 
ligands supports a potential positive prognostic impact of 
T-CTLA-4 [45]. Few studies have investigated the prog-
nostic impact of CTLA-4 expression in NSCLC. Two large 
studies reported high gene expression of CTLA-4 to medi-
ate a negative impact, and no significant association with 
survival, respectively [23, 25]. Similar to a smaller study by 
Salvi et  al., we observed no significant prognostic impact 
of high PT T-CTLA-4, when assessing protein expression 
by IHC and applying the 14D3 mAb, except for a positive 
association with DSS for ADC patients, which was not 
significant in multivariate analysis [24]. Apparently, these 
studies illustrate a dual role of CTLA-4 expression in tumor 
cells, and highlight the importance of further investigating 
mechanisms of upregulation, impact on prognosis and dif-
ferences in CTLA-4 expression in tumor cells by cancer 
subtypes.
High stromal CTLA-4 expression was associated with 
an independent positive outcome for the SCC subgroup, 
and showed a positive trend for all patients. Even though 
several stromal cell types were positive for CTLA-4 in the 
NSCLC tumors, immune cell staining intensity was the 
predominant determinant of the S-CTLA-4 score. A posi-
tive impact of CTLA-4 on outcome has also been reported 
for the expression in breast cancer related interstitial lym-
phocytes [41]. CTLA-4 in T cells is normally upregulated 
only upon activation. Hence, high stromal CTLA-4 expres-
sion presumably reflects a tumor microenvironment highly 
infiltrated by activated immune cells, even though immu-
nosuppressive subtypes such as regulatory T cells and 
exhausted cytotoxic T cells also express CTLA-4 [46]. We 
infer that the positive association between S-CTLA-4 and 
survival in SCC tumors can be explained by the presence of 
a tumor microenvironment in which anti-tumor immunity 
properties dominate. The contrasting lack of prognostic 
effect for S-CTLA-4 in ADC patients may illustrate exist-
ing differences in the balance between activated immune 
cells with immunosuppressive and anti-tumor immune 
properties between histological NSCLC subgroups. This 
is in line with the differences observed in immunotherapy 
treatment efficacy according to histological subgroups in 
NSCLC [22, 47, 48]. Furthermore, we observed S-CTLA-4 
to be extensively correlated with other immune markers, 
especially with S-CD8 and S-PD-L1, which were recently 
found to be independent positive prognostic markers in 
the same patient population [27, 30]. Interestingly, it has 
been suggested that a pre-existing immune-active tumor 
microenvironment is what mediates the anti-tumor activity 
of CTLA-4 blockade; hence, one may speculate that stro-
mal CTLA-4 expression may have potential as a predictive 
marker for anti-CTLA-4 treatment in NSCLC patients [49].
In conclusion, we hypothesize that CTLA-4 expression 
by tumor cells in locoregional LN+, but not PTs, may pre-
dict poor survival in NSCLC patients. If validated in larger, 
confirmatory studies, tumor cell CTLA-4 expression in 
LN+ is a promising prognostic marker, readily available 
in surgically treated patients. Its prognostic impact should 
also be investigated for other metastatic sites. Furthermore, 
despite its acknowledged immunosuppressive mechanism 
of action, we hypothesize that high CTLA-4 expression in 
the stromal compartment mirrors immune cell activation, 
and speculate that analysis of S-CTLA-4 may allow tai-
lored checkpoint blockade to individual patients.
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